Deal bags Flugen a vaccine delivery micro-device

By Nick Taylor

- Last updated on GMT

Related tags Vaccine

Flugen has secured the exclusive rights to Ratio’s novel vaccine delivery technology, which is a disposable micro-device that it claims can improve efficacy and compliance.

The benefits of the device are claimed to be most pronounced among the over 65s, who are the also more at risk from influenza, with efficacy increasing most among this group and the easy, pain free delivery hoped to improve vaccination rates.

Flugen will now begin preclinical testing of the device using its cell-based trivalent influenza vaccines (TIVs), with the company hoping to submit an investigational new drug (IND) application to the US Food and Drug Administration (FDA) in the second half of 2010.

Paul Radspinner, president and CEO of FluGen, said: “This exciting vaccine-delivery technology from Ratio is an important expansion of FluGen’s product pipeline​.

It will allow the company to offer the $6bn(€4.5bn) influenza vaccine market not only superior vaccines, but an easy-to-use, painless delivery technology that increases vaccine effectiveness. FluGen looks forward to advancing this valuable product through our pipeline with one or more TIVs​.”

The micro-device is a similar size to a poker chip and contains a miniature fluidic pump that is activated at the press of a button. This sends the vaccine from its reservoir, through a set of microneedles and delivers it intradermally or into the skin.

Unlike traditional delivery techniques the vaccine is not delivered into the muscle and Flugen believes this has the potential to increase the treatments efficacy, which it claims can be as low as 20 per cent with syringe delivery in some patients.

Terms of the license agreement were not disclosed.

Related topics Ingredients Delivery technologies

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars